Wezlana Chronology: From Biosimilar To Interchangeable In The Blink Of An Eye

 
• By Sue Sutter

Pink Sheet’s Drug Review Profile looks at the timeline behind the development and FDA review of Amgen’s Wezlana (ustekinumab-auub), an interchangeable biosimilar to Janssen’s Stelara.

Drug Review Profile: Wezlana
• Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews